Menu
Menu
SOPHiA GENETICS will be attending the International Society for Liquid Biopsy Annual Meeting (ISLB) in Madrid, Spain! We look forward to connecting with leaders and innovators to discuss the evolving role of data in shaping the future of healthcare. Meet us at Booth #21.
More information is coming soon!
Join SOPHiA GENETICS at the European Congress of Pathology (ECP) 2026 in Stockholm, Sweden. We are excited to engage with the pathology community and share how our technology helps transform complex data into practical insights.
Visit our page again shortly for more information!
SOPHiA GENETICS will be at the Association for Molecular Pathology Europe Congress (AMP Europe) 2026 in Tallinn, Estonia. We are looking forward to discussing how we support laboratories and healthcare institutions with scalable, data-driven solutions.
Additional details will be available soon!
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to Chicago! Join us on May 29th at 3:00 PM CST at The Metropolitan in Chicago, IL, for its 2026 edition.
Two years ago, SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) started a liquid biopsy revolution that has since grown into a global shift in precision oncology access. This forum brings together the minds behind that shift to reflect on what was built, its real-world impact, and reveal what comes next.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From MSK to the World, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don't miss this unique opportunity and reserve your spot now!
Le invitamos a participar en este exclusivo encuentro que reunirá a expertos y líderes clínicos para explorar los avances más recientes en medicina de precisión y genómica aplicada.
El evento contará con la participación del Presidente de SOPHiA GENETICS, quien compartirá la visión global de la compañía, así como con especialistas que abordarán el impacto de NGS en hemato-oncología y las tendencias futuras del área.
Asimismo, el evento destacará experiencias reales de clientes que compartirán su práctica clínica utilizando la plataforma SOPHiA DDM™, ofreciendo una perspectiva concreta sobre su impacto en el diagnóstico y la toma de decisiones.
A continuación, encontrará la agenda preliminar del evento.
What: SOPHiA GENETICS Exclusive Networking event
Where: Savoy Hotel
Date: 21 de abril
Time: 19:00 - 22:00
19:00 – 19:30
Leading Innovation to Impact: SOPHiA GENETICS’ Global Vision
Ross Muken, President, SOPHiA GENETICS
19:30 – 20:00
Panel NGS para LLC: implementación y validación analítica.
Mauro García-Montenegro
Jefe Anatomia Patologia, Argenetics
20:00 - 20:30
Paneles de genes mediante NGS: Transformando el estudio de las neoplasias mieloides
Andrea Bender, Especialista en Bioquímica Clínica Laboratorio de Especialidades Bioquimicas (LEB)
20:30 – 21:00
What’s Next in Hemato-Oncology Genomics
Bruno Piovezan, Subject Matter Expert LATAM, SOPHiA GENETICS
21:00 – 22:00
Cocktails & Networking
Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders
Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.
Connect with your peers and enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform
El GENOMiCS INSIGHTS Day Bogotá se llevará a cabo el próximo 23 de abril, en el Hotel W Bogotá.
Este encuentro reunirá a expertos, líderes clínicos y profesionales del área de la genómica para explorar los avances más recientes en medicina de precisión y el impacto creciente de las tecnologías genómicas en la práctica clínica.
Durante la jornada abordaremos temas clave como la visión global de innovación de SOPHiA GENETICS, las nuevas posibilidades clínicas de la biopsia líquida, experiencias reales de implementación en la práctica clínica con la plataforma SOPHiA DDM™, y nuevas oportunidades para ampliar el análisis genómico mediante exomas optimizados.
Este espacio también busca fomentar el intercambio de experiencias y la conversación entre profesionales del sector, promoviendo el avance de la medicina genómica en la región.
A continuación, encontrará la agenda preliminar del evento.
What: SOPHiA GENETICS Exclusive Networking event
Where: Hotel W Bogotá
Date: 23 de abril
Time: 16:00 - 19:00
16:00 – 16:30
De la innovación al impacto: la visión global de SOPHiA GENETICS.
Ross Muken, President, SOPHiA GENETICS
16:30 – 17:00
Expandiendo las posibilidades clínicas con las soluciones de biopsia líquida de SOPHiA GENETICS.
Luna Rodriguez, Subject Matter Expert LATAM, SOPHiA GENETICS
17:00 - 17:30
Biopsia líquida en la práctica clínica: experiencia real con la plataforma SOPHiA DDM™.
July Katherine Rodriguez Ariza, Directora científica, FICMAC
17:30 – 18:00
Exomas optimizados: una nueva oportunidad para expandir el análisis genómico.
Gabriela Acosta, Sales Executive, LATAM SOPHiA GENETICS
Discover how SOPHiA DDM™ enables accurate analysis across multiple disease areas – from oncology to inherited disorders
Discuss the future of research and healthcare institutions to harness NGS data for quick, robust, and actionable insights, guiding best decisions.
Connect with your peers and enjoy a networking environment with your peers and users of SOPHiA DDM™ Platform
Speaker: Persephone du Parcq, Lead Clinical/Translational Scientist, Synnovis, UK
In this webinar, Dr. Persephone du Parcq shares how Synnovis has deployed the MSK-ACCESS™ powered with SOPHiA DDM™ to support precision oncology through minimally invasive liquid biopsy testing.
The webinar explores current clinical applications of ctDNA analysis, its demonstrated utility in routine healthcare, and key considerations around assay selection, validation strategies, and interpretation challenges including germline findings and clonal haematopoiesis. Practical insights into clinical impact, operational achievements to date, and lessons learned from clinical implementation are also discussed.
Finally, the session looks ahead to future directions for liquid biopsy in oncology, including opportunities to expand clinical adoption and improve patient care through advanced genomic technologies.
We are glad to return to Swiss Biotech Day 2026, where you will have the chance to meet our leadership team for two days of exciting networking, innovation, and insights sharing on the potential of AI-driven solutions to transform precision medicine
The SOPHiA GENETICS team is thrilled to see you at our Fireside chat on Monday, May 4th from 15.30 to 16.15, in Room Delhi – Level 0.
“Liquid Biopsy at a Tipping Point in Precision Oncology”
Join Philippe Menu, MD, PhD, MBA, EVP, Chief Medical & Product Officer, SOPHiA GENETICS, Elena Guerini Rocco, MD, Director of the Oncology Genetics Unit, IEO – Istituto Europeo di Oncologia, and Thomas di Maio, EU/Canada Diagnostic Lead, AstraZeneca for an insightful conversation about the liquid biopsy movement.
The SOPHiA GENETICS™ Global Precision Medicine Forum returns to Chicago! Join us on May 29th at 3:00 PM CST at The Metropolitan in Chicago, IL, for its 2026 edition.
Two years ago, SOPHiA GENETICS and Memorial Sloan Kettering Cancer Center (MSK) started a liquid biopsy revolution that has since grown into a global shift in precision oncology access. This forum brings together the minds behind that shift to reflect on what was built, its real-world impact, and reveal what comes next.
Join Pharma and Biotech leaders, oncology KOLs, and diagnostic partners to explore The Liquid Biopsy Movement: From MSK to the World, and how it is reshaping the future of cancer care.
Across different sessions, the forum will explore:
Don’t miss this unique opportunity and reserve your spot now!
We are thrilled to be at the inaugural World Clinical Biomarkers & Companion Diagnostics Summit Japan. Join us and meet our BioPharma team to learn how we help BioPharma companies address challenges throughout the drug development continuum, enhancing efficiency and precision to accelerate the development of better and more effective precision therapeutics.
The SOPHiA GENETICS team is thrilled to see you join our Plenary Talk.
Plenary talk on Tuesday, May 19th from 12.50 to 1.20 pm.
“Liquid Biopsy in Japan: From Global Vision to Local Reality”
Philippe Menu, MD, PhD, MBA, EVP, Chief Medical & Product Officer, SOPHiA GENETICS
Michel Mommejat, President/Representative Director and Chief Innovation Officer, A.D.A.M. Innovations
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.